Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network-Reference-Cited by-同舟云学术

Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network

Published:2024-02 Issue:2 Volume:18 Page:
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Rose Angela M. C.¹^ORCID,Pozo Francisco²³,Martínez‐Baz Iván³⁴,Mazagatos Clara³⁵^ORCID,Bossuyt Nathalie⁶,Cauchi John Paul⁷^ORCID,Petrović Goranka⁸,Loghin Isabela I.⁹,Vaikutyte Roberta¹⁰,Buda Silke¹¹,Machado Ausenda¹²^ORCID,Duffy Róisín¹³,Oroszi Beatrix¹⁴,Howard Jennifer¹,Echeverria Aitziber³⁴,Andreu Cristina¹⁵,Barbezange Cyril⁶^ORCID,Džiugytė Aušra⁷,Nonković Diana¹⁶,Popescu Corneliu‐Petru¹⁷,Majauskaite Fausta¹⁸^ORCID,Tolksdorf Kristin¹¹,Gomez Verónica¹²,Domegan Lisa¹³^ORCID,Horváth Judit Krisztina¹⁴,Castilla Jesús³⁴^ORCID,García Miriam¹⁹,Demuyser Thomas²⁰,Borg Maria‐Louise⁷,Tabain Irena⁸,Lazar Mihaela²¹,Kubiliute Ieva¹⁸,Dürrwald Ralf¹¹^ORCID,Guiomar Raquel¹²^ORCID,O'Donnell Joan¹³,Kristóf Katalin¹⁴,Nicolay Nathalie²²,Bacci Sabrina²²,Kissling Esther¹^ORCID,

Affiliation:

1. Epiconcept Paris France

2. National Centre for Microbiology Institute of Health Carlos III Madrid Spain

3. Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) Madrid Spain

4. Instituto de Salud Pública de Navarra‐IdiSNA Pamplona Spain

5. National Centre for Epidemiology Institute of Health Carlos III Madrid Spain

6. Sciensano Brussels Belgium

7. Department for Health Regulation Health Promotion and Disease Prevention Msida Malta

8. Croatian Institute of Public Health Zagreb Croatia

9. St Parascheva Clinical Hospital of Infectious Diseases Iasi Romania

10. Lithuanian University of Health Sciences Kaunas Lithuania

11. Robert Koch Institute Berlin Germany

12. National Institute of Health Dr Ricardo Jorge Lisbon Portugal

13. Health Service Executive–Health Protection Surveillance Centre Dublin Ireland

14. Semmelweis University Budapest Hungary

15. Subdirección de Epidemiología, Dirección General de Salud Pública Servicio Extremeño de Salud Mérida Spain

16. Teaching Public Health Institute of Split‐Dalmatia County Split Croatia

17. Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases Bucharest Romania

18. Institute of Clinical Medicine, Medical Faculty Vilnius University Vilnius Lithuania

19. Dirección General de Salud Pública, Departamento de Sanidad Gobierno de Aragón Zaragoza Spain

20. Department of Microbiology and Infection control UZ Brussel Brussels Belgium

21. “Cantacuzino” National Military–Medical Institute for Research and Development Bucharest Romania

22. European Centre for Disease Prevention and Control Stockholm Sweden

Abstract

AbstractWe conducted a multicentre hospital‐based test‐negative case–control study to measure vaccine effectiveness (VE) against PCR‐confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: −23–36); 20% (95% CI: −4–39) against A(H3N2) and 56% (95% CI: 22–75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.

Funder

European Centre for Disease Prevention and Control

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.13255

Reference12 articles.

1. World Health Organization (WHO).Recommended composition of influenza virus vaccines for use in the 2022‐2023 northern hemisphere influenza season [Internet].2022. Available at:https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2022-2023/202202_recommendation.pdf

2. World Health Organisation and European Centre for Disease Prevention and Control.Flu News Europe season overview.2023. Available at:https://flunewseurope.org/SeasonOverview

3. I‐MOVE influenza and COVID‐19 networks.I‐MOVE‐COVID‐19 hospital network VE generic protocol [internet]. Paris France: Epiconcept;2021. Available at:https://www.imoveflu.org/wp-content/uploads/2021/03/08feb2021_draft_generic_VE_protocol_hospital-based_COVID-19_v07.pdf

4. European Centre for Disease Prevention and Control.Core protocol for ECDC VEBIS studies of COVID‐19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory‐confirmed with SARS‐CoV‐2 or seasonal influenza ‐ version 2.0 [Internet]. Stockholm: ECDC;2023. Available at:https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-vaccine-effectiveness-sari-protocol-version-2.pdf

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic evolution of influenza during the 2023–2024 season, the johns hopkins health system;Journal of Clinical Virology;2024-10

2. Influenza epidemiology and vaccine effectiveness during the 2023/2024 season in Italy: A test-negative case-control study;International Journal of Infectious Diseases;2024-10

3. Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study;Human Vaccines & Immunotherapeutics;2024-08-29

4. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024;Eurosurveillance;2024-02-22